In contrast, 28 day-long Ang II infusion caused suprarenal AAA development, with ApoE−/−Mfap4−/− mice showing a significantly lower incidence rate (62%) compared to 93% incidence rate in ApoE−/− mice (Figures 2A–C). The gene discussed is APOE; the disease is triple-A syndrome.